Together, these results suggest that IL-8-CXCR1/2 signaling is associated with gefitinib resistance [59], thus providing a possible mechanism whereby high plasma IL-8 levels mediate PFS in EGFR TKI-treated patients with EGFR mutation-positive lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.